In patients suffering from depression who were treated with escitalopram, concomitant 3-week administration of the MR agonist fludrocortisone led to a faster response to the antidepressant treatment compared to patients who received the MR antagonist spironolactone or placebo (Otte et al. 2010). Here, NR3C2 is linked to depressive symptom measurement.